ObjectiveTo evaluate the safety, functional protection, and clinical efficacy of three-dimensional (3D) complete laparoscopic radical rectal cancer resection using natural orifice specimen extraction surgery (NOSES). MethodsAccording to the inclusion and exclusion criteria, the patients who received laparoscopic radical rectal cancer surgery in the Second Affiliated Hospital of Chongqing Medical University from January 2019 to December 2020 were retrospectively collected. The patients underwent 3D complete laparoscopic radical rectal cancer resection using NOSES were allocated to the observation group, while traditional laparoscopic assisted radical rectal cancer resection were allocated to the control group. The indexes of safety, functional protection, and clinical efficacy were compared between the two groups. ResultsA total of 80 patients were included in this study, including 40 patients in the observation group and 40 patients in the control group. There were no statistical differences in the baseline data between the two groups (P>0.05). There were no statistical differences between the two groups in the total operative time, intraoperative bleeding, number of lymph node dissection, positive rates of intraperitoneal tumor cells and bacterial culture, and tumor recurrence and metastasis rate (P>0.05). Compared with the control group, the first getting out of bed time, exhausting and defecating time after operation were earlier, meanwhile the postoperative pain score, use of analgesics, and the occurrence of severe low anterior resection syndrome were better in the observation group (P<0.05). The incidence of postoperative overall complications in the observation group was lower than that in the control group (P<0.01). The postoperative hospital stay was shorter and the hospitalization costs were less in the observation group as compared with the control group (P<0.05). ConclusionFrom results of this study, 3D complete laparoscopic radical rectal cancer resection using NOSES is safe and feasible, its functional protection and clinical efficacy are better than those of traditional laparoscopic assisted radical rectal cancer resection.
ObjectiveTo explore the clinical value of immunotherapeutic drugs represented by programmed cell death-1 (PD-1) / programmed cell death ligand-1 (PD-L1) blockades for treatment of advanced gastric cancer. MethodThe latest literatures about the clinical studies of PD-1/PD-L1 blockades for the treatment of advanced gastric cancer were retrieved and reviewed. ResultsThe corresponding clinical trials relevant to PD-1/PD-L1 blockades had been conducted in the treatment, biomarkers, and resistance to drugs for advanced gastric cancer. The PD-1/PD-L1 blockades single drug or its in combination with chemical drugs or (and) targeted drugs for the treatment of advanced gastric cancer or gastroesophageal junction cancer had shown a good efficacy in some patients. The patients who benefited from PD-1/PD-L1 blockades might be a population with specific molecular characteristics, but the resistance to drugs during the therapy process affected its therapeutic effect. ConclusionFrom the progress of this review, PD-1/PD-L1 blockades bring benefits to some patients with advanced gastric cancer, but more biomarkers which can predict the therapeutic effect need to be found to optimize the drug regimen, and the resistance to drugs mechanism needs to be further studied.
ObjectiveTo understand the latest research progress in the treatment of advanced gastric cancer (AGC) and explore the optimal treatment strategy. Method The latest literature on the treatment of AGC was retrieved and reviewed. Results For patients with AGC, chemotherapy, radiotherapy, targeted therapy, immunotherapy, palliative therapy, nutritional support, and traditional Chinese medicine therapy were currently adopted in clinic, the combination of them were used usually. Some patients obtained good therapeutic effects by new chemotherapy drugs and antibody conjugated drugs. In the era of first-line immunotherapy or targeted therapy, first-line immunotherapy alone, immunotherapy in combination with chemotherapy, double immunotherapy, and immunotherapy combined with anti-angiogenesis targeted drugs for AGC had represented some survival benefits. ConclusionsThe research, development, and widespread application of new anti-tumor drugs have continuously expanded the treatment methods for AGC. The development of tumor molecular biology provides an opportunity for the treatment of AGC, and the precise diagnosis and treatment pattern guided by molecular typing is gradually maturing. However, the treatment of AGC is still facing challenges. In the era of precision medicine, facing the higher heterogeneity of gastric cancer, the dilemma of precise treatment of drugs for AGC, and the research and development of new anti-tumor drugs, the optimal treatment mode of AGC still needs more clinical exploration. It is necessary to comprehensively consider various aspects such as the patient’s physical condition, previous treatment status, and drug accessibility.
Objective To explore the clinical value, latest research progress, and clinical controversy of total neoadjuvant therapy (TNT) in locally advanced rectal cancer (LARC). Method We searched and reviewed on the latest literatures about studies of the clinical research of TNT in LARC. Results TNT could make the tumor downstage rapidly and improve the patients’ treatment compliance. In terms of organ preservation rate, 3-year disease-free survival and pathological complete remission rate, TNT had advantages and was a especial potential treatment strategy compared with traditional methods. Conclusions TNT decreases local recurrence rate and improves the long-term survival. For LARC patients with strong desire for organ preservation, TNT is a good treatment choice and has the value of clinical promotion.